Goserelin plus anastrozole as first-line endocrine therapy for premenopausal women with oestrogen receptor (ER) positive advanced breast cancer (ABC)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 731-731 ◽  
Author(s):  
K.-L. Cheung ◽  
L. Winterbottom ◽  
R. Owers ◽  
J. Robertson
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Oestrogen Receptor ◽  
Premenopausal Women ◽  
Advanced Breast ◽  
First Line ◽  
Er Positive

Results of first line endocrine therapy for advanced breast cancer in premenopausal women with skeletal metastases only

The Breast ◽  
1993 ◽  
Vol 2 (3) ◽  
pp. 203-204 ◽  
Author(s):  
W. Jonat ◽  
M. Kaufmann ◽  
R. Blamey ◽  
A. Howell ◽  
J. Collins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Premenopausal Women ◽  
Advanced Breast ◽  
Skeletal Metastases ◽  
First Line

Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group

2003 ◽  
Vol 21 (11) ◽  
pp. 2101-2109 ◽  
Author(s):  
Henning Mouridsen ◽  
Mikhail Gershanovich ◽  
Yan Sun ◽  
Ramón Pérez-Carrión ◽  
Corrado Boni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Postmenopausal Women ◽  
Endocrine Therapy ◽  
Advanced Breast ◽  
Phase Iii ◽  
Karnofsky Performance Score ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Purpose: To analyze overall survival (OS) and update efficacy data for letrozole versus tamoxifen as first-line therapy in postmenopausal women with locally advanced or metastatic breast cancer. Patients and Methods: This multicenter phase III trial randomly assigned 916 patients with hormone receptor–positive or unknown tumors letrozole 2.5 mg (n = 458) or tamoxifen 20 mg (n = 458) daily until disease progression. Optional cross-over was permitted at the treating physician’s discretion. This report updates efficacy at a median follow-up of 32 months. Results: The superiority of letrozole to tamoxifen was confirmed for time to progression (median, 9.4 v 6.0 months, respectively; P < .0001), time to treatment failure (median, 9 v 5.7 months, respectively; P < .0001), overall objective response rate (32% v 21%, respectively; P = .0002), and overall clinical benefit. Median OS was slightly prolonged for the randomized letrozole arm (34 v 30 months, respectively). Although this difference in OS is not significant, survival was improved in the randomized letrozole arm over the first 2 years of the study. Approximately one half of the patients in each arm crossed over. Total duration of endocrine therapy (“time to chemotherapy”) was significantly longer (P = .005) for patients initially on letrozole (median, 16 months) than for patients initially on tamoxifen (median, 9 months). Time to worsening of Karnofsky performance score was significantly delayed with letrozole compared with tamoxifen (P = .001). Conclusion: This study documents the superiority of letrozole over tamoxifen in first-line endocrine therapy in postmenopausal women with advanced breast cancer.

scholarly journals Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC)

2019 ◽  
Vol 30 ◽  
pp. iii53 ◽  
Author(s):  
D. Tripathy ◽  
G.N. Hortobagyi ◽  
A. Chan ◽  
S.-A. Im ◽  
S. Chia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Safety Analysis ◽  
Advanced Breast ◽  
First Line

scholarly journals Pooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC)

2019 ◽  
Vol 30 ◽  
pp. iii49-iii50
Author(s):  
D. Tripathy ◽  
G.N. Hortobagyi ◽  
A. Chan ◽  
S.-A. Im ◽  
S. Chia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Advanced Breast ◽  
First Line ◽  
Efficacy Analysis
Sign in / Sign up

Export Citation Format

Share Document